Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: gw842166x, prs-211375, s-777469 +4 | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 4 Parkinson's papers of 374 | 0.79 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6325
Sealed predictions
- CNR2 in dopamine neurons, braak-0.28 (p 0.470) → -0.10 (p 0.802)receipt 6332
Swarm cases
receipt 6332: CNR2 in dopamine neurons, braak
- power
- full sample -0.16 (p 0.521, n 18), 95% CI -0.58 to +0.33. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.20 (p 0.434, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.18 (p 0.476, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.05, sign flips 0; without severely affected donors -0.16 (p 0.521, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CNR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts